All In Biotech

Drug Trial Radar · NCT05944224

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

A Randomized, Open-label, Phase Ib/IIa Clinical Study to Evaluate the Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors, Including Advanced Well Differentiated/Dedifferentiated Liposarcoma.

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

63

Planned (sponsor's estimate)

Start

Oct 17, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SPH4336Drug

    SPH4336 Tablets :Orally, 400mg once a day ; 28 days/cycle

  • CadonilimabDrug

    Intravenous infusion, 6mg/Kg,28 days/cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Approximately 2 years

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • Peking University People's Hospital

    Beijing, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

  • Shanghai Sixth People's Hospital

    Shanghai, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, He'nan, China · Recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenzhen, Liaoning, China · Recruiting

  • Xijing Hospital

    Xi’an, Shanxi, China · Recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.